Literature DB >> 11465392

Human adult and foetal liver sulphotransferases: inhibition by mefenamic acid and salicylic acid.

M Vietri1, A Pietrabissa, F Mosca, A Rane, G M Pacific.   

Abstract

1. The aim was to see whether mefenamic acid and salicylic acid had different inhibition profiles for SULT1A1 (substrate: 4-nitrophenol) and SULT1A3 (dopamine) activities and on (-)-salbutamol and minoxidil sulphation rates in the human adult and mid-gestational foetal livers. 2. The activity (pmolmin(-1) mg(-1) of SULT1A1 was 662 +/- 78 (adult) and 246 +/- 159 (foetus; p = 0.003) and that of SULT1A3 was 24 +/- 4 (adult) and 121 +/- 90 (foetus; p = 0.030). The rate (pmol min(-1) mg(-1)) of (-)-salbutamol sulphation was 109 +/- 27 (adult) and 117 +/- 34 (foetus; p = (0.144) and that of minoxidil sulphation was 202 +/- 38 (adult) and 108 +/- 44 (foetus; p = 0.001). 3. With mefenamic acid as an inhibitor, the IC50 (microM) for SULT1A1 was 0.2 +/- 0.004 (adult) and 0.01 +/- 0.002 (foetus; p = 0.001); for SULT1A3 it was 76 +/- 6 (adult) and 77 +/- 13 (foetus; p = 0.889); for the rate of ( )-salbutamol sulphation it was 0.07 +/- 0.005 (adult) and not determinable (foetus) and for minoxidil sulphation it was 1.6 +/- 0.7 (adult) and 0.15 +/- 0.04 (foetus; p = 0.076). 4. With salicylic acid as an inhibitor, the IC50 (microM) for SULT1A1 was 30 +/- 2 (adult) and 25 +/- 1 (foetus; p = 0.011); for SULT1A3 it was 690 +/- 36 (adult) and 570 +/- 16 (foetus; p = 0.229); for the rate of ( )-salbutamol sulphation it was 93 +/- 11 (adult) and 344 +/- 42 (foetus; p = 0.010); with minoxidil as substrate, the IC50 was not determinable. 5. In summary, SULT1A1, SULT1A3 and the sulphotransferases towards (-)-salbutamol and minoxidil had measurable activities in the mid-gestational human foetal liver. Mefenamic acid was a more potent inhibitor than salicylic acid of both human adult and foetal liver SULT1A1 and SULT1A3 activities. Foetal liver SULT1A1 was more susceptible than adult liver SULT1A1 to inhibition by mefenamic acid and salicylic acid. These results are consistent with the view that sulphotransferases develop early in the human foetal liver and drugs may inhibit their activities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465392     DOI: 10.1080/00498250110043481

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

1.  On the Molecular Basis Underlying the Metabolism of Tapentadol Through Sulfation.

Authors:  Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

2.  Effects of the human SULT1A1 polymorphisms on the sulfation of acetaminophen,O-desmethylnaproxen, and tapentadol.

Authors:  Mohammed I Rasool; Ahsan F Bairam; Saud A Gohal; Amal A El Daibani; Fatemah A Alherz; Maryam S Abunnaja; Eid S Alatwi; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Pharmacol Rep       Date:  2018-12-10       Impact factor: 3.024

Review 3.  Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Authors:  Y J Blumenfeld; M F Reynolds-May; R B Altman; Y Y El-Sayed
Journal:  J Perinatol       Date:  2009-11-19       Impact factor: 2.521

Review 4.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

5.  Integration of Placental Transfer in a Fetal-Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus.

Authors:  Paola Mian; Karel Allegaert; Sigrid Conings; Pieter Annaert; Dick Tibboel; Marc Pfister; Kristel van Calsteren; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.